Capricor Therapeutics, Inc.
CAPR
$6.51
-$0.09-1.36%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -7.92% | -63.44% | 1.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -7.92% | -63.44% | 1.38% |
| Cost of Revenue | 76.31% | 70.40% | 46.42% | 17.74% | 41.82% |
| Gross Profit | -158.37% | -205.38% | -259.43% | -148.39% | -74.15% |
| SG&A Expenses | 85.48% | 49.01% | 24.62% | 14.64% | 7.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.11% | 64.66% | 40.83% | 17.02% | 33.42% |
| Operating Income | -139.14% | -143.36% | -500.78% | -89.52% | -49.62% |
| Income Before Tax | -135.56% | -149.04% | -833.81% | -96.49% | -49.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -135.56% | -149.04% | -833.81% | -96.49% | -49.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -135.56% | -149.04% | -833.81% | -96.49% | -49.32% |
| EBIT | -139.14% | -143.36% | -500.78% | -89.52% | -49.62% |
| EBITDA | -142.41% | -147.40% | -651.99% | -91.99% | -49.94% |
| EPS Basic | -64.13% | -71.09% | -542.17% | -53.33% | -18.78% |
| Normalized Basic EPS | -64.10% | -70.08% | -534.19% | -53.43% | -18.82% |
| EPS Diluted | -64.13% | -71.09% | -542.17% | -53.33% | -18.78% |
| Normalized Diluted EPS | -64.10% | -70.08% | -534.19% | -53.43% | -18.82% |
| Average Basic Shares Outstanding | 43.55% | 45.55% | 45.15% | 28.17% | 25.68% |
| Average Diluted Shares Outstanding | 43.55% | 45.55% | 45.15% | 28.17% | 25.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |